Bruce Levin, Ph.D., is Professor and Past Chair of the Department of Biostatistics at Columbia University’s Mailman School of Public Health. He has a long-standing interest in statistical methodology for clinical trials, public health, and the law. Using sequential statistical methods, he has published on innovative trial designs, e.g., designs that minimize ethical costs, designs that emphasize the selection paradigm rather than the significance testing paradigm, and novel designs such as the comparative selection trial which combines features of both paradigms. An examples is the QALS trial (high-dose coenzyme Q10 in ALS disease), a phase II design that combined a selection phase with a non-superiority (futility) phase utilizing the same data. In May of 2009 Dr. Levin gave a short course to the FDA/CDER biostatistics group entitled, “Selection Methods in Clinical Trials.” Dr. Levin enjoys putting theory into practice and has served as the senior statistical consultant on several multicenter randomized clinical trials in the field of stroke neurology and cardiology, including the WARCEF trial funded by NINDS (Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction), the WARSS trial (Warfarin versus Aspirin in Recurrent Stroke Study), the GAIN Americas trial, and the CABG Patch trial. In addition to these aging-related diseases, Dr. Levin has collaborated for many years with epidemiologists Zena Stein and Jennie Kline studying reproductive aging. He has also served for the last 20 years as the Director of the Statistics, Epidemiology, and Data Management (SED) Core of the HIV Center for Clinical and Behavioral Studies.

 stroke neurology and cardiology